Stocks To Buy

Remember when everyone said "software is eating the world"? Well, plot twist: AI is now eating the software. We're witnessing what smart money is calling "SaaSmaggedon" – the slow-motion collapse of the traditional software-as-a-service model. And honestly? It was bound to happen. Here's the thing that's keeping SaaS executives up at night: AI doesn't need a seat at the table. For 15 years, SaaS companies had the perfect racket – charge $30-100 per employee per month, and watch revenue grow as companies ...
Read More About This

So Disney just announced they're getting a new CEO, and honestly? It's about time. Meet Josh D'Amaro, the guy who's been running Disney's theme parks and apparently still rides the attractions himself to make sure they don't suck. That's either dedication or the best job perk ever. Here's the deal: Disney has been having what you might call a "rough patch" lately. And by rough patch, I mean their stock has dropped 42% over five years while everyone else was making ...
Read More About This

So Booking Holdings (BKNG) decided to take a little tumble yesterday, dropping 3.56% while the rest of the market was having its own mini-meltdown. You know, just your typical Tuesday in 2026 where a stock worth over $4,000 per share decides to shed some weight. Here's the thing about BKNG – when a stock that expensive moves, it's like watching a luxury yacht hit a speed bump. The company that basically owns your vacation planning (you know, the one behind Booking.com, ...
Read More About This

The FDA said no. Then it said yes. And Moderna shareholders are having a very good Wednesday because of it. Shares of the biotech company surged more than 6% after Moderna announced that the Food and Drug Administration reversed its earlier decision and agreed to review the company’s experimental mRNA flu vaccine, mRNA-1010. Just last week, the FDA had refused to even accept the application for review — citing the lack of a comparison study with a vaccine currently used by ...
Read More About This

When the biggest chip company on the planet starts selling its stakes in AI startups, you pay attention. Nvidia’s latest 13F filing — dropped Tuesday after the bell — reveals the AI kingmaker has been quietly reshuffling its investment portfolio, and the moves tell a story about where the smart money thinks this AI cycle is actually heading. The exits were surgical. Nvidia dumped its entire positions in Applied Digital, ARM Holdings, Recursion Pharmaceuticals, and WeRide during the fourth quarter of ...
Read More About This

For years, Wall Street treated Palantir Technologies like that friend who is clearly talented but charges way too much for dinner. The data analytics company had a cult following among retail investors, but analysts kept their distance, turned off by a valuation that made nosebleed seats look cheap. That dynamic just flipped. After Palantir shares tumbled 25% since the start of 2026, more than half of Wall Street analysts now rate the stock the equivalent of a buy. That is a ...
Read More About This

Remember when everyone said software was eating the world? Well, plot twist: AI is now eating the software. For the past 15 years, Software-as-a-Service (SaaS) was basically a money printer. Build a decent dashboard, slap a monthly fee on it, and watch the cash roll in as companies hired more people who needed more "seats." It was beautiful in its simplicity. But here's the thing nobody saw coming: AI doesn't need a seat at the table. Think about it. If one AI agent ...
Read More About This

Bayer's eight-year Roundup nightmare may finally have an expiration date — and the market can't decide if it's relieved or terrified. On Tuesday, Bayer's Monsanto unit filed a proposed $7.25 billion class-action settlement in Missouri state court designed to resolve roughly 65,000 pending lawsuits and cap future claims over a 21-year period. The lawsuits allege that Roundup, the world's most widely used weedkiller, causes non-Hodgkin lymphoma and other cancers. Bayer denies wrongdoing and maintains decades of studies show the product is ...
Read More About This